Combination therapy with transcatheter arterial infusion chemotherapy using miriplatin and percutaneous radiofrequency ablation for hepatocellular carcinoma

Norihiro Imai, Kenji Ikeda, Yuya Seko, Tasuku Hara, Atsushi Ohno, Naoki Matsumoto, Yusuke Kawamura, Tetsuya Hosaka, Masahiro Kobayashi, Satoshi Saitoh, Hitomi Sezaki, Norio Akuta, Fumitaka Suzuki, Yoshiyuki Suzuki, Yasuji Arase, Hiromitsu Kumada

Research output: Contribution to journalArticlepeer-review

Abstract

Miriplatin is a platinum complex developed to treat hepatocellular carcinoma (HCC) via administration into the hepatic artery as a sustained-release suspension in iodized oil. We retrospectively evaluated the efficacy of combination therapy with transcatheter arterial infusion chemotherapy using miriplatin and percutaneous radiofrequency ablation for HCC in 11 patients. Immediately after transcatheter arterial infusion chemotherapy using miriplatin, we performed radiofrequency ablation. The greatest long-axis and short-axis dimensions of the area coagulated after combination therapy were 42 mm (35-80 mm) and 34 mm (32-60 mm), respectively. During follow-up (median 12 months), there was no recurrence from the same subsegment. No serious adverse events were observed. These results suggested that using the combination therapy, it is possible to finish one treatment session for patient with HCC.

Original languageEnglish
Pages (from-to)351-354
Number of pages4
JournalKanzo/Acta Hepatologica Japonica
Volume53
Issue number6
DOIs
Publication statusPublished - Jul 2012
Externally publishedYes

Keywords

  • Hepatocellular carcinoma
  • Miriplatin
  • Radiofrequency ablation

Fingerprint

Dive into the research topics of 'Combination therapy with transcatheter arterial infusion chemotherapy using miriplatin and percutaneous radiofrequency ablation for hepatocellular carcinoma'. Together they form a unique fingerprint.

Cite this